ArticleOncoimmunology2026

Sex-based considerations in the choice for a TLR9 or TLR7/8 agonist to arm the sentinel lymph node in early-stage melanoma.

Jessica C L Notohardjo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.